GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Debt-to-Revenue

Dechra Pharmaceuticals (LSE:DPH) Debt-to-Revenue : 0.66 (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Dechra Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £3.9 Mil. Dechra Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £500.6 Mil. Dechra Pharmaceuticals's annualized Revenue for the quarter that ended in Jun. 2023 was £768.2 Mil. Dechra Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.66.


Dechra Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for Dechra Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Debt-to-Revenue Chart

Dechra Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.69 0.52 0.48 0.66

Dechra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.48 0.47 0.68 0.66

Competitive Comparison of Dechra Pharmaceuticals's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dechra Pharmaceuticals's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's Debt-to-Revenue falls into.



Dechra Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Dechra Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.9 + 500.6) / 761.5
=0.66

Dechra Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.9 + 500.6) / 768.2
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.


Dechra Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Dechra Pharmaceuticals (LSE:DPH) Business Description

Traded in Other Exchanges
Address
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines